GlassScriptPhysician profile
Joshua M Usen
NPI 1447257399
$1,694.08
in general payments reported to CMS, 2019-2025
24 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $93.94 · 2021: $229 · 2022: $598 · 2023: $289 · 2024: $120 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $575 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.41 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $475.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $207.94 | 2021-2022 | |
| Lilly USA, LLC | $162.10 | 2019-2025 | Mounjaro |
| Glaxosmithkline, LLC. | $144.95 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Idorsia Pharmaceuticals US INC | $117.16 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $73.69 | 2020-2025 | Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $73.17 | 2024-2025 | Voquezna |
| Baxter Healthcare | $57.46 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Dexcom, INC. | $55.93 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $52.00 | 2022-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $30.38 | 2022 | |
| Allergan, INC. | $28.75 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.15 | 2024 | Jardiance |
| Pfizer INC. | $26.86 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.39 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $20.55 | 2025 | Ohtuvayre |
| Collegium Pharmaceutical, INC. | $20.03 | 2024 | Belbuca |
| Sentynl Therapeutics, INC. | $17.49 | 2019 | |
| Amgen INC. | $16.25 | 2025 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $16.25 | 2022 | |
| Amarin Pharma, INC. | $15.52 | 2019 | |
| Merck Sharp & Dohme LLC | $12.84 | 2019 | |
| Gilead Sciences, INC. | $11.16 | 2020 | |
| Clarus Therapeutics INC. | $5.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Usen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.